Abstract
Pharmacometrics—pharmacokinetics/pharmacodynamics (PK/PD) modeling and simulation—has been used to inform drug development decisions for more than two decades and has gained increasing support from the pharmaceutical industry, academia, and regulatory agencies. With the regulatory encouragement on model-informed drug development and the recognition of high-impact emerging applications, pharmacometric analysis currently plays an important role throughout a drug’s life cycle, from the early translational stage to the confirmatory phase 3 and regulatory approval, and even into the post-marketing trials. This chapter provides a brief introduction to pharmacometric analysis approaches including pharmacokinetic models, PK/PD models, physiologically based pharmacokinetic models, quantitative systems pharmacology models, and model based meta-analysis models. Aspects of model development are also discussed such as software, modeling work flow, and major model components, with a focus on population modeling analysis. Finally, case studies are provided to highlight the broad applications of this evolving science in drug development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ariens EJ (ed.) (1964) Molecular Pharmacology: The mode of action of biologically active compounds. Academic Press, New York.
Beal S, Sheiner LB (1984) NONMEM I Users Guide. Technical Report, Division of Clinical Pharmacology, University of California at San Francisco.
Bonate PL (ed.) (2011) Pharmacokinetic-pharmacodynamic modeling and simulation, Springer, New York.
Chien JY, Friedrich S, Heathman MA, et al. (2005) Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:e544-59.
Crawford M (2016) The when and why of quantitative systems pharmacology. AAPS News Magazine. December.
Csajka C, Verotta D (2006) Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 33:227-79.
Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-78.
De Winter W, Dunne A, Woot deTrixhe X, et al. (2016) Dynamic population PK/PD modeling and simulation supports similar efficacy in HbA1c response with once or twice-daily dosing of canagliflozin. Br J Clin Pharmacol doi: https://doi.org/10.1111/bcp.13180.
Ette EI, Williams PJ (2007) Pharmacometrics: impacting drug development and pharmacotherapy. In: Ette EI, Williams PJ (eds.) Pharmacometrics: The science of quantitative pharmacology, John Wiley & Sons, Inc., New Jersey, p 1-21.
EFPIA MID3 Workgroup (2016) Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol 5:93-122.
EMA (2008) Reporting the results of population pharmacokinetic analyses. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001284.jsp&mid=WC0b01ac0580032ec5. Assessed 28 Jan 2017.
EMA (2016) Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf. Assessed 28 Jan 2017.
FDA (1999) Guidance for Industry: Population Pharmacokinetics. Food and Drug Administration. http://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf. Assessed 28 Jan 2017.
FDA (2003) Guidance for Industry: Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications. Food and Drug Administration. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf. Assessed 28 Jan 2017
FDA (2004) Challenge and Opportunity on the Critical Path to New Products. Food and Drug Administration. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf. Assessed 28 Jan 2017
Forschungsinstitut B, Dettlti L, Freerksen E, et al. (1962) Pharmakokinetik und Arzneimitteldosierung (Pharmacokinetics and Drug Dosage). Kolloquium im Forschungsinstitut Borstel vom 25. bis 27. Oktober 1962. In: Antibiot Chemother. vol. 12, Karger Publishers, Basel, Switzerland (1964)
Gabrielsson J, Weiner D (2007) Pharmacokinetic concepts. In: Gabrielsson J, Weiner D (eds.). Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 4th Edition. Swedish Pharmaceutical Press, Stockholm, Sweden, p 11-224.
Gibaldi M, Levy G (1976) Pharmacokinetics in clinical practice: 1. Concepts. JAMA 235:1864–1867.
Gobburu JV, Lesko LL (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49: 291-301.
Gobburu JV (2013) Intermediate PKPD Modeling. Course: PHAR747, University of Maryland School of Pharmacy.
Holford NHG, Hale M, Ko H, et al. (1999) Simulation in drug development: good practices. Originally published by the Centre for Drug Development Science http://holford.fmhs.auckland.ac.nz/docs/simulation-in-drug-development-good-practices.pdf. Assessed 28 Jan 2017
Hu C, Wasfi Y, Zhuang Y, et al. (2014) Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis. J Pharmacokinet Pharmacodyn 4:239-50.
Hutmacher MM, Kowalski KG (2015) Covariate selection in pharmacometric analyses: a review of methods Br J Clin Pharmacol 79:132-47
Jones H, Rowland-Yeo K (2013) Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol 14:e63
Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-19
Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17-20.
Kimko H, Duffull S (eds.) (2003) Simulation of clinical trials in drug development. Marcel-Dekker, New York.
Kimko H, Peck C (eds.). (2010) Clinical trial simulations: applications & trends. AAPS Advances in the Pharmaceutical Sciences Series, Springers, New York.
Lee JY, Garnett CE, Gobburu JV, et al. (2011) Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 50:627–635.
Levy G (1966) Kinetics of pharmacologic effects. Clin Pharm Ther 7:362–372.
Mager DE, Kimko H (eds.) (2016) Systems pharmacology and pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, Springers, New York.
Mandema JW, Gibbs M, Boyd RA, et al. (2011) Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther 90:766-9.
Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 26:e6.
Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 17:e38.
Nagashima R, O’Reilly R, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10:22–35.
Olson SC, Bockbrader H, Boyd RA, et al. (2000) Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis. Clin Pharmacokinet 38:449-59.
Pang S, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-53.
Peck C, Barr WH, Benet LZ, et al. (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharm Ther 51: 465-473.
Reigner BG, Williams PE, Patel IH, et al. (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142-52.
Rowland M, Benet L (1982) Pharmacometrics: a new journal section. J Pharmacokinet Biopharm 10:349–350.
Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45: 229–239.
Sheiner L, Rosenberg B, Melmon K (1972) Modeling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:441–459.
Sheiner LB, Stanski DR, Vozeh S, et al. (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 25:358-71.
Sheiner L (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291.
Segre G (1968) Kinetics of interaction between drugs and biological system. Farmaco Sci 23:907–918.
Sorger PK, Allerheiligen SRB, Abernethy DR, et al. (2011) Quantitative and systems pharmacology in the postgenomic era: new approaches to discovering and understanding therapeutic drugs and mechanisms. An NIH White Paper from the QSP Workshop Group, http://www.nigms.nih.gov/Training/Documents/SystemsPharmaWPSorger2011.pdf. Assessed 28 Jan 2017
Teorell T (1937) Kinetics of distribution of substances administered to the body. The extravascular modes of administration. Arch Int Pharmacodyn Ther 57:205–255.
Upton RN, Mould DR (2014) Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol 2:e88.
Vicini P, van der Graaf PH (2013) Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin Pharmacol Ther 93:379-81.
Wagner JG (1981) History of pharmacokinetics. Pharmacol Ther 12:537-62.
Widmark E, Tandberg J (1924) Uber die bedingungen fur die akkumulation indifferenter narkoliken theoretische bereckerunger. Biochem Z 147:358–369.
Xu Y, Hartmann G, Gibson C, et al. (2014) Utility of physiologically based pharmacokinetics in pediatric drug development. In: Abstracts of the 5th American Conference of Pharmacometrics. Las Vegas, NV, 12-15 October 2014.
Xu Y, Li YF, Zhang D, et al. (2016) Characterizing class-specific exposure-viral load suppression response of HIV antiretrovirals using a model-based meta-analysis. Clin Transl Sci 9:192-200.
Zhou H (2003) Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 43:211-27.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Xu, Y., Kimko, H. (2020). Pharmacometrics: A Quantitative Decision-Making Tool in Drug Development. In: Marchenko, O.V., Katenka, N.V. (eds) Quantitative Methods in Pharmaceutical Research and Development. Springer, Cham. https://doi.org/10.1007/978-3-030-48555-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-48555-9_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-48554-2
Online ISBN: 978-3-030-48555-9
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)